These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 913016)

  • 1. Pindolol availability in hypertensive patients with normal and impaired renal function.
    Chau NP; Weiss YA; Safar ME; Lavene DE; Georges DR; Milliez PL
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):505-10. PubMed ID: 913016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous and oral pindolol in hypertensive patients with chronic renal failure.
    Safar ME; Chau NP; Levenson JA; Simon AC; Weiss YA
    Clin Sci Mol Med Suppl; 1978 Dec; 4():275s-277s. PubMed ID: 282067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
    Lavene D; Weiss YA; Safar ME; Loria Y; Agorus N; Georges D; Milliez PL
    J Clin Pharmacol; 1977; 17(8-9):501-8. PubMed ID: 893736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between renal function and elimination kinetics of pindolol in man.
    Oie S; Levy G
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):115-6. PubMed ID: 1233259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prazosin kinetics in essential hypertension.
    Chau NP; Flouvat BL; Le Roux E; Safar ME
    Clin Pharmacol Ther; 1980 Jul; 28(1):6-11. PubMed ID: 7389255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pindolol on renal function II. Effects on intravenous and prolonged oral dosing.
    Boner G; Wainer E; Rosenfeld JB
    Clin Pharmacol Ther; 1982 Oct; 32(4):423-7. PubMed ID: 7116756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function during acute and long term pindolol treatment in hypertensive patients with normal and decreased glomerular filtration.
    Rosenfeld J; Boner G; Wainer E
    Br J Clin Pharmacol; 1982; 13(Suppl 2):237S-240S. PubMed ID: 7104147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of unchanged pindolol in patients with impaired renal function.
    Ohnhaus EE
    Br J Pharmacol; 1973 Mar; 47(3):620P-621P. PubMed ID: 4730841
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolism of pindolol in patients with renal failure.
    Ohnhaus EE; Heidemann H; Meier J; Maurer G
    Eur J Clin Pharmacol; 1982; 22(5):423-8. PubMed ID: 7117354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furosemide kinetics in renal failure.
    Tilstone WJ; Fine A
    Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function.
    Aronoff G; Brier M; Mayer ML; Barbalas M; Aogaichi K; Sloan R; Brazzell R; Massarella J
    J Clin Pharmacol; 1991 Jan; 31(1):38-44. PubMed ID: 2045527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the bioavailability of pindolol in malabsorption syndromes.
    Evard D; Aubry JP; Le Quintrec Y; Cheymol G; Cheymol A
    Br J Clin Pharmacol; 1984 Oct; 18(4):632-7. PubMed ID: 6487506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of pindolol absorption in malabsorption syndromes].
    Evard D; Le Quintrec Y; Aubry JP; Cheymol G; Cheymol A
    Gastroenterol Clin Biol; 1983 Apr; 7(4):398-404. PubMed ID: 6873552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mepindolol in patients with chronic renal failure.
    Krause W; Kampf D; Fischer HC
    Eur J Clin Pharmacol; 1984; 27(4):429-33. PubMed ID: 6519149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.
    Meier J; Nüesch E
    Br J Clin Pharmacol; 1977 Jun; 4(3):371-2. PubMed ID: 901706
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.
    MacDonald NJ; Grant AC; Rodger RS; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1991 Jun; 31(6):697-700. PubMed ID: 1678272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function.
    Sketris IS; Skoutakis VA; Acchiardo SR; Meyer MC
    Eur J Clin Pharmacol; 1981; 20(6):453-7. PubMed ID: 7286056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective renal clearance of pindolol in humans.
    Hsyu PH; Giacomini KM
    J Clin Invest; 1985 Nov; 76(5):1720-6. PubMed ID: 4056049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure.
    Craig RM; Murphy P; Gibson TP; Quintanilla A; Chao GC; Cochrane C; Patterson A; Atkinson AJ
    J Lab Clin Med; 1983 Mar; 101(3):496-506. PubMed ID: 6827177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.